Stem cell therapies to modulate harmful immune responses in kidney disease: progress toward clinical validation

Area of Science:

• Immunology
• Nephrology
• Regenerative Medicine

Background:

• Kidney diseases involve immune-mediated tissue injury and inflammation, impacting acute kidney injury (AKI), chronic kidney disease (CKD), and kidney transplantation (KTx).
• Stem cells possess immunomodulatory properties, reprogramming immune responses from pro-inflammatory to anti-inflammatory and pro-repair states through paracrine mechanisms.

Purpose of the Study:

• To review mechanisms of immune-mediated kidney injury and relevant stem cell therapies.
• To evaluate clinical trial evidence for stem cell therapies in human kidney disease and KTx.
• To identify barriers hindering the clinical translation of stem cell therapies for kidney disease.

Main Methods:

• Literature review of preclinical and clinical studies on stem cell therapies for kidney diseases.
• Analysis of molecular and cellular mechanisms underlying stem cell immunomodulation in kidney injury models.
• Critical assessment of clinical trial data for efficacy and safety of stem cell products in kidney disease patients.

Main Results:

• Extensive preclinical data support stem cell efficacy in AKI, CKD, and KTx models using various stem cell types (e.g., mesenchymal stem cells, induced pluripotent stem cells).
• Clinical translation of stem cell therapies for kidney disease faces significant challenges, with limited validation of preclinical findings in human trials.
• Identified bottlenecks include understanding complex immune interactions, standardizing cell products, and demonstrating consistent therapeutic benefits in diverse patient populations.

Conclusions:

• Stem cell therapies offer a promising avenue for kidney disease management by harnessing their immunomodulatory and regenerative potential.
• Despite strong preclinical evidence, robust clinical validation and overcoming translational hurdles are critical for widespread adoption in nephrology and transplantation.
• Further research and strategic development are needed to bridge the gap between laboratory findings and effective patient treatments for kidney diseases.